SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Immunomedics (IMMU) - moderated -- Ignore unavailable to you. Want to Upgrade?

To: drtom1234 who wrote (45235)1/20/2018 8:28:09 AM
From: sogwap1  Read Replies (1) | Respond to of 63276
 
Hey "Chart Guys", would enjoy your perspective as weekend entertainment. Thanks.



To: drtom1234 who wrote (45235)1/20/2018 1:07:54 PM
From: hearthero1 Recommendation

Recommended By
drtom1234

  Respond to of 63276
 
Dr Tom

Completely agree, great analysis. We consolidate her for a bit and then wait for regulatory, clinical and bench progress. Progress is incremental, we leaped in 2018. The jump up the ladder from 3rd line will occur in refractory cases in breast ca.

Thanks Tom,

DrQ



To: drtom1234 who wrote (45235)1/21/2018 4:36:58 PM
From: idahoranch1  Read Replies (1) | Respond to of 63276
 
<<Previous figures have been as high as 7 billion a year. In addition, the company has stated they are looking also at head and neck cancer, as well as ovarian cancer.>>

And Metastatic prostate cancer. The numbers really could be staggering.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News